Literature DB >> 33507294

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow.

Colin D Godwin1,2, Yi Zhou3, Megan Othus4, Mallette M Asmuth5, Carole M Shaw1, Kelda M Gardner2, Brent L Wood3, Roland B Walter1,2,6,7, Elihu H Estey1,2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33507294      PMCID： PMC7845008          DOI： 10.1182/blood.2020006219

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   25.476


× No keyword cloud information.
  12 in total

1.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

2.  Peripheral blood minimal/measurable residual disease assessed in flow cytometry in acute myeloblastic leukemia.

Authors:  Cécile Guénot; Francis Lacombe; Kaoutar Allou; Florent Dumezy; Jean Feuillard; Franck Geneviève; Estelle Guérin; Julien Guy; Marc Maynadié; Orianne Wagner Ballon; Claude Preudhomme; André Baruchel; Hervé Dombret; Norbert Ifrah; Marie C Béné
Journal:  Leukemia       Date:  2019-02-05       Impact factor: 11.528

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.

Authors:  W Zeijlemaker; A Kelder; Y J M Oussoren-Brockhoff; W J Scholten; A N Snel; D Veldhuizen; J Cloos; G J Ossenkoppele; G J Schuurhuis
Journal:  Leukemia       Date:  2015-09-16       Impact factor: 11.528

5.  Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach.

Authors:  Brent L Wood
Journal:  Curr Protoc Cytom       Date:  2020-06

Review 6.  Measurable residual disease testing in acute myeloid leukaemia.

Authors:  C S Hourigan; R P Gale; N J Gormley; G J Ossenkoppele; R B Walter
Journal:  Leukemia       Date:  2017-04-07       Impact factor: 11.528

7.  Estimation of rank correlation for clustered data.

Authors:  Bernard Rosner; Robert J Glynn
Journal:  Stat Med       Date:  2017-04-11       Impact factor: 2.373

8.  Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.

Authors:  Luca Maurillo; Francesco Buccisano; Alessandra Spagnoli; Giovanni Del Poeta; Paola Panetta; Benedetta Neri; Maria Ilaria Del Principe; Carla Mazzone; Maria Irno Consalvo; Anna Tamburini; Licia Ottaviani; Daniela Fraboni; Chiara Sarlo; Paolo De Fabritiis; Sergio Amadori; Adriano Venditti
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

9.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.

Authors:  Roland B Walter; Sarah A Buckley; John M Pagel; Brent L Wood; Barry E Storer; Brenda M Sandmaier; Min Fang; Boglarka Gyurkocza; Colleen Delaney; Jerald P Radich; Elihu H Estey; Frederick R Appelbaum
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113

Review 10.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Gerrit J Schuurhuis; Michael Heuser; Sylvie Freeman; Marie-Christine Béné; Francesco Buccisano; Jacqueline Cloos; David Grimwade; Torsten Haferlach; Robert K Hills; Christopher S Hourigan; Jeffrey L Jorgensen; Wolfgang Kern; Francis Lacombe; Luca Maurillo; Claude Preudhomme; Bert A van der Reijden; Christian Thiede; Adriano Venditti; Paresh Vyas; Brent L Wood; Roland B Walter; Konstanze Döhner; Gail J Roboz; Gert J Ossenkoppele
Journal:  Blood       Date:  2018-01-12       Impact factor: 25.476
View more
  8 in total

Review 1.  Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.

Authors:  Roland B Walter; Yishai Ofran; Agnieszka Wierzbowska; Farhad Ravandi; Christopher S Hourigan; Lok Lam Ngai; Adriano Venditti; Francesco Buccisano; Gert J Ossenkoppele; Gail J Roboz
Journal:  Leukemia       Date:  2021-03-23       Impact factor: 11.528

2.  Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Authors:  Gege Gui; Christopher S Hourigan
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

3.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.

Authors:  Michael Heuser; Sylvie D Freeman; Gert J Ossenkoppele; Francesco Buccisano; Christopher S Hourigan; Lok Lam Ngai; Jesse M Tettero; Costa Bachas; Constance Baer; Marie-Christine Béné; Veit Bücklein; Anna Czyz; Barbara Denys; Richard Dillon; Michaela Feuring-Buske; Monica L Guzman; Torsten Haferlach; Lina Han; Julia K Herzig; Jeffrey L Jorgensen; Wolfgang Kern; Marina Y Konopleva; Francis Lacombe; Marta Libura; Agata Majchrzak; Luca Maurillo; Yishai Ofran; Jan Philippe; Adriana Plesa; Claude Preudhomme; Farhad Ravandi; Christophe Roumier; Marion Subklewe; Felicitas Thol; Arjan A van de Loosdrecht; Bert A van der Reijden; Adriano Venditti; Agnieszka Wierzbowska; Peter J M Valk; Brent L Wood; Roland B Walter; Christian Thiede; Konstanze Döhner; Gail J Roboz; Jacqueline Cloos
Journal:  Blood       Date:  2021-12-30       Impact factor: 22.113

4.  Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.

Authors:  Jesse M Tettero; Sylvie Freeman; Veit Buecklein; Adriano Venditti; Luca Maurillo; Wolfgang Kern; Roland B Walter; Brent L Wood; Christophe Roumier; Jan Philippé; Barbara Denys; Jeffrey L Jorgensen; Marie C Bene; Francis Lacombe; Adriana Plesa; Monica L Guzman; Agnieszka Wierzbowska; Anna Czyz; Lok Lam Ngai; Adrian Schwarzer; Costa Bachas; Jacqueline Cloos; Marion Subklewe; Michaela Fuering-Buske; Francesco Buccisano
Journal:  Hemasphere       Date:  2021-12-22

5.  Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Tali Azenkot; Brian A Jonas
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

6.  Evaluation of fixed-panel, multicolour ClearLLab 10C at an academic flow cytometry laboratory in Johannesburg, South Africa.

Authors:  Deborah K Glencross; Leanne Swart; Melanie Pretorius; Denise Lawrie
Journal:  Afr J Lab Med       Date:  2022-07-15

7.  Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Authors:  Fabio Guolo; Claudio Cerchione; Chiara Vernarecci; Alessandro Isidori
Journal:  Front Oncol       Date:  2022-09-09       Impact factor: 5.738

8.  AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML.

Authors:  Diana Hanekamp; Jesse M Tettero; Gert J Ossenkoppele; Angèle Kelder; Jacqueline Cloos; Gerrit Jan Schuurhuis
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.